Banque Pictet & Cie SA Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Banque Pictet & Cie SA reduced its stake in Regeneron Pharmaceuticals by 10.8%, resulting in ownership of 5,473 shares valued at approximately $2.87 million.
• Regeneron Pharmaceuticals reported an earnings beat with an EPS of $12.89 for the quarter, exceeding analyst estimates of $8.43 and growing revenue by 3.6% year over year.
• Equities research analysts have given Regeneron a consensus rating of "Moderate Buy" with an average target price of $817.67, indicating positive outlooks from several institutions.

Banque Pictet & Cie SA trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,473 shares of the biopharmaceutical company's stock after selling 664 shares during the period. Banque Pictet & Cie SA's holdings in Regeneron Pharmaceuticals were worth $2,873,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the business. Kingswood Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its stake in shares of Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 19 shares during the last quarter. Private Trust Co. NA boosted its stake in shares of Regeneron Pharmaceuticals by 13.1% during the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 19 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after purchasing an additional 19 shares during the last quarter. Finally, Cove Private Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.5% during the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock worth $292,000 after purchasing an additional 20 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective on the stock. BMO Capital Markets increased their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Finally, Citigroup reiterated a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Trading Up 1.5%

NASDAQ REGN opened at $563.90 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,070.00. The company's 50 day moving average price is $569.79 and its 200 day moving average price is $571.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market capitalization of $59.77 billion, a price-to-earnings ratio of 14.21, a PEG ratio of 1.77 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the firm posted $11.56 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.